289 related articles for article (PubMed ID: 26707699)
1. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.
Berthold E; Månsson B; Gullstrand B; Geborek P; Saxne T; Bengtsson AA; Kahn R
Scand J Rheumatol; 2018 Jan; 47(1):22-26. PubMed ID: 28485187
[TBL] [Abstract][Full Text] [Related]
3. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
[TBL] [Abstract][Full Text] [Related]
4. 90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis.
Cecamore C; Marsili M; Salvatore R; Troiani R; D'Egidio M; Tinari N; Pelliccia P; Chiarelli F; Marcovecchio ML; Breda L
Mod Rheumatol; 2018 Jul; 28(4):637-641. PubMed ID: 29157059
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
6. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
[TBL] [Abstract][Full Text] [Related]
7. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
9. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
Su Y; Yang YH; Chiang BL
Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
[TBL] [Abstract][Full Text] [Related]
10. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
11. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
12. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
13. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
[TBL] [Abstract][Full Text] [Related]
14. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis.
Bašić J; Vojinović J; Jevtović-Stoimenov T; Despotović M; Sušić G; Lazarević D; Milošević V; Cvetković M; Pavlović D
Clin Rheumatol; 2019 Jan; 38(1):117-124. PubMed ID: 30128913
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
19. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
[TBL] [Abstract][Full Text] [Related]
20. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
